A recent report has noted a context-dependent oncogenic role for BRF2 (not a known oncogene in most cancers) in driving a subset of HER2+ breast tumours which do not express ERRB2/HER2 [63]; the authors call BRF2 an ‘alternative driver’ of HER2+ tumours. The gene discussed is BRF2; the disease is neoplasm.